Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-19 in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06277011Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-19 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 3 months. Started Feb 2023; status: recruiting.
02
Drugs
Meta10-19
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06277011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277011.